Edwards Lifesciences Corporation (EW)
Chart Events
Performance Outlook
| Previous Close | 84.25 |
| Open | 84.25 |
| Bid | 82.18 x 800 |
| Ask | 82.24 x 800 |
| Day's Range | 81.25 - 84.85 |
| 52 Week Range | 51.51 - 92.08 |
| Volume | 1,800,471 |
| Avg. Volume | 2,533,860 |
| Market Cap | 51.279B |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | 63.16 |
| EPS (TTM) | 1.30 |
| Earnings Date | Apr 21, 2021 - Apr 26, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 94.25 |
- TheStreet.com
Tighten Your Sell Stops on Edwards Lifesciences
Prices have yet to reach our $104 price target and remain above $79 but we still want to check the charts again. In this updated daily bar chart of EW, below, we can see that prices have been in a choppy sideways pattern since September. The On-Balance-Volume (OBV) line has been declining since the beginning of 2021 and tells us that sellers of EW have been more aggressive.
- Simply Wall St.
Many Would Be Jealous Of Edwards Lifesciences' (NYSE:EW) Returns On Capital
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...
- PR Newswire
Edwards RESILIA Tissue Aortic Valve Demonstrates Favorable Safety and Efficacy at Five Years
Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE clinical trial that demonstrate Edwards' bioprosthetic surgical aortic valve with the company's novel RESILIA tissue platform show favorable safety and hemodynamic performance through a median of five years follow-up. The data were presented at the 57th annual meeting of the Society of Thoracic Surgeons.
